Glucose- and lipid-modulating drugs may shift toward a thinner, less inflammatory, and more metabolically active state.
Evidence
This review summarizes in vitro and in vivo evidence on statins, PPAR-gamma agonists, AMPK activators, GLP-1 receptor agonists, and SGLT2 inhibitors, with the most consistent epicardial adipose tissue effects reported for SGLT2 inhibitors and GLP-1 receptor agonists.
Caveat
As a review of mixed mechanistic and pharmacological evidence, it synthesizes current findings rather than testing a single intervention or clinical endpoint directly.
Simplified
(EAT) is a metabolically active visceral fat depot located between the myocardium and the visceral pericardium, exerting direct paracrine and vasocrine effects on the heart and coronary vessels. Under physiological conditions, EAT supports myocardial energy metabolism and thermoregulation through fatty acid supply and adaptive metabolic flexibility. In cardiometabolic disorders such as obesity, type 2 diabetes, and heart failure, EAT undergoes pathological remodelling characterized by increased thickness, adipocyte hypertrophy, immune cell infiltration, and secretion of pro-inflammatory and fibrotic mediators. These alterations contribute to myocardial fibrosis, stiffness, and coronary atherosclerosis, particularly in heart failure with preserved ejection fraction. Pharmacological modulation of EAT has therefore emerged as a promising therapeutic approach in cardiovascular prevention. Agents such as statins, peroxisome proliferator-activated receptor gamma agonists, adenosine monophosphate-activated protein kinase activators, glucagon-like peptide-1 receptor agonists, and sodium-glucose cotransporter 2 inhibitors exert both systemic and depot-specific effects. They reduce EAT thickness, suppress inflammatory signalling, enhance insulin sensitivity, and promote adipocyte browning and oxidative metabolism. Among these, sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists show the most consistent effects in shifting EAT towards a less inflammatory and more metabolically active phenotype. The goal of this review is to provide an overview of current pharmacological interventions that influence EAT and to summarize how much is known about their molecular mechanisms from in vitro and in vivo studies. The target audience includes cardiovascular researchers and clinicians seeking to better understand how metabolic and antidiabetic therapies modulate cardiac fat biology and function.
Key numbers
20%
Reduction in volume
Observed with semaglutide in patients with type 2 diabetes and obesity.
9%
9% decrease in volume
Measured in type 2 diabetes patients over 24 weeks.
Full Text
We can’t show the full text here under this license.
